Patent DE28826C successfully refreshed from Google Patents.
EP1550673A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Polyclonal antibodies, preparation method thereof and use of same
Assignee: Araclon Biotech SL
•
Filing: 2003-08-13
•
Granted: —
•
Expires: 2023-08-13
Abstract
Abstract Polyclonal antibodies,preparation method thereof and use of same. The invention relates to polyclonal antibodies which specifically recognize, and have a strong affinity with, the two most significant amyloid peptides, Aβ40 and Aβ42. The invention also relates to the use thereof in assessing drugs which activate the degradation of amyloid peptides characteristic of Alzheimer's disease as well as drugs which inhibit the formation of same.
Inventors
- 👤 Manuel Sarasa Barrio
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 11:48
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4711; C07K16/00; C07K16/18; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; G01N33/6896
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
117 words
Polyclonal antibody for specific recognition of the main forms of the amyloid
beta peptide, Aβ40 and Aβ42, obtainable by immunization of mammals with
a protein conjugated with a peptide selected from the group formed by: the peptide of SEQ ID NO: 1, the peptide of SEQ ID NO: 2, the peptide
of SEQ ID NO: 3, the peptide of SEQ ID NO: 4; the peptides with a sequence arising from elimination of the N-terminal
and/or C-terminal amino acid residues from SEQ ID NO: 1, SEQ ID
NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4; and the peptides resulting from adding the amino acid residues
necessary for protein conjugation to any of the aforementioned
sequences.
Claim 2
Dependent Claim
68 words
Polyclonal antibody according to Claim 1, characterized in that the
immunization is performed with a peptide selected from the group
comprising: the peptide of SEQ ID NO: 1; the peptides with a sequence resulting from elimination of N-terminal
and/or C-terminal amino acid residues from SEQ ID NO: 1; and the peptides resulting from adding the amino acid residues
necessary for protein conjugation to any of the aforementioned
sequences.
Claim 3
Dependent Claim
68 words
Polyclonal antibody according to Claim 1, characterized in that the
immunization is performed with a peptide selected from the group
comprising: the peptide of SEQ ID NO: 2; the peptides with a sequence resulting from elimination of N-terminal
and/or C-terminal amino acid residues from SEQ ID NO: 2; and the peptides resulting from adding the amino acid residues
necessary for protein conjugation to any of the aforementioned
sequences.
Claim 4
Dependent Claim
68 words
Polyclonal antibody according to Claim 1, characterized in that the
immunization is performed with a peptide selected from the group
comprising: the peptide of SEQ ID NO: 3; the peptides with a sequence resulting from elimination of N-terminal
and/or C-terminal amino acid residues from SEQ ID NO: 3; and the peptides resulting from adding the amino acid residues
necessary for protein conjugation to any of the aforementioned
sequences.
Claim 5
Dependent Claim
68 words
Polyclonal antibody according to Claim 1, characterized in that the
immunization is performed with a peptide selected from the group
comprising: the peptide of SEQ ID NO: 4; the peptides with a sequence resulting from elimination of N-terminal
and/or C-terminal amino acid residues from SEQ ID NO: 4; and the peptides resulting from adding the amino acid residues
necessary for protein conjugation to any of the aforementioned
sequences.
Claim 6
Dependent Claim
22 words
Polyclonal antibody according to any of the previous Claims 1 to 5, characterized in that the protein is Keyhole Limpet Hemocyanin (KLH).
Claim 7
Dependent Claim
19 words
Polyclonal antibody according to any of the previous Claims 1 to 6, characterized in that the mammals are rabbits
Claim 8
Dependent Claim
21 words
Substantially pure peptide characterized in that it has a sequence of amino
acids selected from the group defined in Claim 1.
Claim 9
Dependent Claim
19 words
Peptide according to Claim 8, characterized in that the sequence is selected
from the group defined in Claim 2.
Claim 10
Dependent Claim
15 words
Peptide according to Claim 9, characterized in that the sequence is SEQ ID
NO: 1.
Claim 11
Dependent Claim
19 words
Peptide according to Claim 8, characterized in that the sequence is selected
from the group defined in Claim 3.
Claim 12
Dependent Claim
15 words
Peptide according to Claim 11, characterized in that the sequence is SEQ ID
NO: 2.
Claim 13
Dependent Claim
19 words
Peptide according to Claim 8, characterized in that the sequence is selected
from the group defined in Claim 4.
Claim 14
Dependent Claim
15 words
Peptide according to Claim 13, characterized in that the sequence is SEQ ID
NO: 3.
Claim 15
Dependent Claim
19 words
Peptide according to Claim 8, characterized in that the sequence is selected
from the group defined in Claim 5.
Claim 16
Dependent Claim
15 words
Peptide according to Claim 15, characterized in that the sequence is SEQ ID
NO: 4.
Claim 17
Dependent Claim
27 words
Use of a peptide according to any of the previous Claims 8 to 16, for
obtaining polyclonal antibodies by conjugation to a protein and immunization
of mammals.
Claim 18
Dependent Claim
15 words
Use according to Claim 17, characterized in that the protein is keyhole
limpet hemocyanin (KLH).
Claim 19
Dependent Claim
16 words
Use according to the previous Claims 17 and 18, characterized in that the
mammals are rabbits.
Claim 20
Dependent Claim
42 words
Method for obtaining polyclonal antibodies for the specific recognition of the
main forms of the beta amyloid protein, Aβ40 and Aβ42, characterized in
that mammals are immunized with a protein conjugated to a peptide
selected from the group defined in Claim 1.
Claim 21
Dependent Claim
15 words
Method according to Claim 20, characterized in that the protein is keyhole
limpet hemocyanin (KLH).
Claim 22
Dependent Claim
18 words
Method according to any of the previous Claims 20 or 21, characterized in
that the mammals are rabbits.
Claim 23
Dependent Claim
53 words
Method for detection of the presence or absence of the amyloid proteins
Aβ40 and Aβ42 in a sample, characterized in that it comprises bringing said
sample into contact with an antibody defined according to Claim 1, and
detecting the presence or absence of the complex formed by said amyloid
proteins and said antibody.
Claim 24
Dependent Claim
49 words
Assay method for drugs which activate the degradation of amyloid peptides
characteristic of Alzheimer's disease, as well as drugs which inhibit the
formation of same, through use of the polyclonal antibodies described in
Claim 1, characterized in that an embryonic chicken egg is used as the
animal assay model.
Claim 25
Dependent Claim
42 words
Use of the embryonic chicken egg as an animal assay model for assaying
both activating drugs of amyloid peptide degradation and inhibitors of their
production, through the use of polyclonal antibodies as markers of the
presence or absence of said amyloid peptides.
Claim 26
Dependent Claim
18 words
Use according to Claim 25, characterized in that the polyclonal antibodies
used are those defined in Claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.